Thompson Davis & Co’s Ocugen OCGN Stock Holding History

Thompson Davis & Co’s Portfolio OCGN Stock Details OCGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-75	Closed	-$8K	–	1147
2017 Q1	$8K	Buy	+75	New	+$7.57K	0.01%	762

Other funds holding OCGN

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

SMV

Sofinnova Management VIII Menlo Park, California $183M AUM 4.18% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Thompson Davis & Co's OCGN Position: Q2 2017 in Review

Thompson Davis & Co sold out of Ocugen (OCGN) in Q2 2017, closing a stake of 75 shares — an estimated $8K sold.

Thompson Davis & Co first reported a position in OCGN in Q1 2017 and held it in 1 quarter. The position peaked at $8K in Q1 2017. 22 funds tracked by Wall St. Rank hold OCGN as of Q2 2017.

Thompson Davis & Co reported no remaining Ocugen position as of Q2 2017 after selling out during the quarter.
Thompson Davis & Co sold 75 Ocugen shares in Q2 2017, an estimated $8K.
Thompson Davis & Co first reported a position in Ocugen in Q1 2017 and held it in 1 quarter.
Thompson Davis & Co's Ocugen position peaked at $8K in Q1 2017.
22 funds tracked by Wall St. Rank held Ocugen as of Q2 2017.

Based on Thompson Davis & Co's 13F filing for Q2 2017, filed 10 Aug 2017.